In the original article, there was a mistake in Figure 1 as published. The images used for the group of OVX+U were from a different study. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Figure 1
Ulinastatin inhibits bone loss induced by OVX. (A) μ-CT images of the trabecular bone of distal femoral metaphysis from the SHAM, OVX, and OVX + ulinastatin groups. (B) The trabecular structural parameters of the distal femur: trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). Data are presented as means ± SD. n = 10 and *P < 0.05.
The original article has been updated.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
ulinastatin, uPAR, osteoclast, MAPKs, NF-kB, RANKL, osteoporosis
Citation
Huang J-m, Ren R-y, Bao Y, Guo J-c, Xiang W, Jing X-z, Shi J, Zhang G-x, Li L, Tian Y, Kang H and Guo F-j (2018) Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR. Front. Pharmacol. 9:1128. doi: 10.3389/fphar.2018.01128
Received
07 September 2018
Accepted
14 September 2018
Published
09 October 2018
Volume
9 - 2018
Edited and reviewed by
Wolff Mayer Kirsch, Loma Linda University Medical Center (LLUMC), United States
Updates
Copyright
© 2018 Huang, Ren, Bao, Guo, Xiang, Jing, Shi, Zhang, Li, Tian, Kang and Guo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hao Kang kanghao100@vip.sina.comFeng-jin Guo fguo@tjh.tjmu.edu.cn
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.